Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annu...
April 28 2021 - 8:00AM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage
gene therapy company focused on developing life-changing treatments
for severe neurological diseases, today announced multiple data
presentations at the American Society of
Gene and Cell Therapy (ASGCT) 24th Annual Meeting
taking place virtually on May 11-14, 2021. Oral presentations
include the first reporting on the company’s novel capsid
technology.
The ASGCT abstracts are now available
at https://www.asgct.org/, with full meeting content available
for 30 days for registered attendees.
Details for the oral presentations are as
follows:
Title: RNA-driven Evolution of AAV Capsid
Libraries Identifies Variants with High Transduction
Efficiency in Non-Human Primate Central Nervous
SystemSession: Novel AAV Capsids
for Brain, Eye and Muscle
TissuesDate/time: May 11,
2021, 5:45-6:00 p.m. ETAbstract number:
51
Title: Efficacy of a Vectorized Anti-Tau
Antibody Using Systemic Dosing of a Blood Brain Barrier
Penetrant AAV Capsid in Mouse Models
of TauopathiesSession: Preclinical
Gene Therapy for Neurologic Disorders
IIDate/time: May 12, 2021, 7:00-7:15
p.m. ETAbstract number: 105
Title: Separation of Empty Capsids from
Full Capsids for AAV Gene Therapy Using a Flow Through and
Step Elution
ApproachSession: Lentivral Vector ManufacturingDate/time: May
14, 2021, 1:45-2:00 p.m. ETAbstract number:
228
Details for the poster presentations are as
follows:
Title: Developing an AAV Delivered Gene
Therapy for Chronic Pain through Inhibition of NaV1.7
ExpressionSession: Neurologic DiseasesDate/time: May
11, 2021, 8:00-10:00 a.m. ETAbstract number:
548
Title: Ultrafiltration Behavior of
Adeno-Associated Viral Vectors (AAVs) in Gene Therapy: Process
Considerations for High
Concentration UF/DFSession: Vector
Product Engineering, Development
or ManufacturingDate/time: May 11,
2021, 8:00-10:00 a.m. ETAbstract number:
835
Title: Expression of AAV Rep78 and Rep52
from Distal Baculovirus loci for Production of Gene Therapy
Vectors: Proof-of-Concept and Initial
OptimizationSession: Vector
Product Engineering, Development
or ManufacturingDate/time: May 11,
2021, 8:00-10:00 a.m. ETAbstract number:
847
Details for the digital presentations are as
follows:
Title: Increasing Baculovirus/Sf9 Platform
Productivity by Developing a Fed-Batch Production
ProcessDate: May 11-14, 2021Abstract
number: 845
Title: Characterizing the Impact of Shear
on SF9 Cells Used in the Baculovirus Expression System for
Recombinant AAV Gene Therapy Vector
ProductionDate: May 11-14, 2021
Abstract number: 856
Voyager is also presenting an Industry Sponsored Symposium
titled "Advancing AAV Gene Therapy for CNS Disease," scheduled for
Wednesday, May 12, 2021 at 2:00 p.m. ET. The symposium will feature
the following speakers and presentations:
David Schaffer, Ph.D.: “Building a Better AAV Capsid for CNS
Gene Therapies”
Guangping Gao, Ph.D.: “Optimizing the Transgene for AAV CNS Gene
Therapies”
Mark Richardson, M.D., Ph.D.: “Evolving Approaches to Direct
Delivery of AAV CNS Gene Therapies”
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy
company focused on developing life-changing treatments for severe
neurological diseases. Voyager is committed to advancing the field
of AAV gene therapy through innovation and investment in vector
engineering and optimization, manufacturing, and dosing and
delivery techniques. Voyager’s wholly owned and partnered pipeline
focuses on severe neurological diseases for which effective new
therapies are needed, including Parkinson’s disease, Huntington’s
disease, Friedreich’s ataxia, and other severe neurological
diseases. For more information on Voyager Therapeutics, please
visit the company’s website
at www.voyagertherapeutics.com or
follow @VoyagerTx on Twitter and LinkedIn.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
Investors:investors@voyagertherapeutics.com
Media:Sheryl
SeapyW2Opure949-903-4750sseapy@purecommunications.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024